Vir Biotechnology reports positive results for hepatitis D combo in first pivotal trial

Vir Biotechnology announced that its chronic hepatitis D treatment met its primary goal in the first of three late‑stage studies. The trial evaluated a once‑monthly combination therapy that includes tobevibart.

In the study, 44% of patients receiving the regimen achieved the predefined efficacy endpoint, marking a notable response in a disease with limited therapeutic options.

The positive data positions Vir against established players such as Gilead and Mirum, potentially reshaping the competitive landscape for hepatitis D therapies.